同步合并头颈部癌的食管鳞状细胞癌的治疗
Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer.
作者信息
Morita Masaru, Egashira Akinori, Nakaji Y U, Kagawa Masaki, Sugiyama Masahiko, Yoshida Daisuke, Ota Mitsuhiko, Ikebe Masahiko, Masuda Muneyuki, Inoue Yojiro, Kunitake Naonobu, Toh Yasushi
机构信息
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
出版信息
In Vivo. 2017 Sep-Oct;31(5):909-916. doi: 10.21873/invivo.11146.
BACKGROUND/AIM: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC).
PATIENTS AND METHODS
Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection.
RESULTS
Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%.
CONCLUSION
The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.
背景/目的：本研究旨在明确食管鳞状细胞癌（ESCC）与头颈部癌（HNC）同步发生时的治疗策略。
患者与方法
对91例ESCC与HNC同步发生的患者的治疗结果进行评估。38例患者接受同步根治性放化疗（CRT），15例患者接受同步手术切除。
结果
在接受同步CRT的患者中，14例（40%）出现不良事件（3 - 5级），包括1例因吸入性肺炎死亡。22例ESCC患者（58%）和19例HNC患者（50%）观察到完全缓解。五年生存率为44%。同步手术后无院内死亡；然而，4例患者出现术后并发症。五年总生存率为70%。
结论
ESCC与HNC同步发生时的治疗必须通过采用适合每个病例的策略来决定。同步CRT和同步手术切除都是可行且有效的治疗选择。
Zotero 插件